Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Kevin B. Kim et al.|The Lancet|2024Cited by 729
CD74 promotes the formation of an immunosuppressive tumor microenvironment in triple-negative breast cancer in mice by inducing the expansion of tolerogenic dendritic cells and regulatory B cellsBianca Pellegrino, Idit Shachar, Keren David et al.|PLoS Biology|2024Cited by 30
Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune CellsThuy Tran, Lucia B. Jilaveanu|Cancers|2021Cited by 14